Evidence-Based Clinical Guidelines for Chronic Constipation 2023
The Japan Gastroenterological Association published the first version of its clinical guidelines for chronic constipation 2023. Based on the latest evidence, these guidelines describe the definition, classification, diagnostic criteria, diagnostic testing methods, epidemiology, pathophysiology, and treatment of chronic constipation. They include flowcharts for both diagnosis and treatment of chronic constipation. In the treatment of chronic constipation, the first step involves differentiating between secondary forms, such as organic disease-associated constipation, systemic disease-associated constipation, and drug-induced constipation. The next step is to determine whether the chronic constipation stems from a motility disorder, a form of primary chronic constipation. For functional constipation and constipation-predominant irritable bowel syndrome, treatment should be initiated after evaluating symptoms like reduced bowel movement frequency type or defecation difficulty type. The first line of treatment includes the improvement of lifestyle habits and diet therapy. The first drugs to consider for oral treatment are osmotic laxatives. If these are ineffective, secretagogues and ileal bile acid transporter inhibitors are candidates. However, stimulant laxatives are exclusively designated for as-needed use. Probiotics, bulk-forming laxatives, prokinetics, and Kampo medicines, for which there is insufficient evidence, are considered alternative or complementary therapy. Providing the best clinical strategies for chronic constipation therapy in Japan, these clinical guidelines for chronic constipation 2023 should prove useful for its treatment worldwide. The Japan Gastroenterological Association published the first version of its clinical guidelines for chronic constipation 2023. Based on the latest evidence, these guidelines describe the definition, classification, diagnostic criteria, diagnostic testing methods, epidemiology, pathophysiology, and treatment of chronic constipation. They include flowcharts for both diagnosis and treatment of chronic constipation. In the treatment of chronic constipation, the first step involves differentiating between secondary forms, such as organic disease-associated constipation, systemic disease-associated constipation, and drug-induced constipation. The next step is to determine whether the chronic constipation stems from a motility disorder, a form of primary chronic constipation. For functional constipation and constipation-predominant irritable bowel syndrome, treatment should be initiated after evaluating symptoms like reduced bowel movement frequency type or defecation difficulty type. The first line of treatment includes the improvement of lifestyle habits and diet therapy. The first drugs to consider for oral treatment are osmotic laxatives. If these are ineffective, secretagogues and ileal bile acid transporter inhibitors are candidates. However, stimulant laxatives are exclusively designated for as-needed use. Probiotics, bulk-forming laxatives, prokinetics, and Kampo medicines, for which there is insufficient evidence, are considered alternative or complementary therapy. Providing the best clinical strategies for chronic constipation therapy in Japan, these clinical guidelines for chronic constipation 2023 should prove useful for its treatment worldwide.
Authors
- Atsushi Nakajima (ORCID: https://orcid.org/0000-0002-6263-1436)
- Koji Nakada (ORCID: https://orcid.org/0000-0002-4472-1008)
- Yoshiyuki Mishima (ORCID: https://orcid.org/0000-0001-5261-6411)
- Akira Torii (ORCID: https://orcid.org/0000-0003-0854-2974)
- Shiko Kuribayashi (ORCID: https://orcid.org/0000-0002-5067-552X)
- Naotaka Ogasawara (ORCID: https://orcid.org/0000-0002-7762-8512)
- Hidenori Ohkubo (ORCID: https://orcid.org/0000-0002-7367-6402)
- Motoyori Kanazawa (ORCID: https://orcid.org/0000-0003-1953-3336)
- Tatsuhiro Masaoka
- Kazuhide Higuchi (ORCID: https://orcid.org/0000-0002-4142-2272)
- Hiroto Miwa (ORCID: https://orcid.org/0000-0001-9844-642X)
- Chika Kusano
- Noboru Misawa (ORCID: https://orcid.org/0000-0002-9272-174X)
- Akinari Sawada (ORCID: https://orcid.org/0000-0002-0590-3693)
- Kazuki Kakimoto (ORCID: https://orcid.org/0000-0003-0564-2793)
- Kunio Kasugai (ORCID: https://orcid.org/0000-0002-0002-6548)
- Shota Takano
- Hidejiro Kawahara (ORCID: https://orcid.org/0000-0002-8618-1556)
- Tomohisa Takagi (ORCID: https://orcid.org/0000-0002-6119-4828)
- Hiromi Kataoka (ORCID: https://orcid.org/0000-0001-9491-0723)
- Akihito Nagahara (ORCID: https://orcid.org/0000-0001-5979-4384)
- Mariko Hojo (ORCID: https://orcid.org/0000-0001-9671-5585)
- Fukudo Shin
- Noriaki Manabe (ORCID: https://orcid.org/0000-0002-5010-3708)
- Ryota Hokari (ORCID: https://orcid.org/0000-0002-8511-2540)
- Sayuri Yamamoto
- Yasuhiro Fujiwara (ORCID: https://orcid.org/0000-0002-1229-5446)
- Toshihiko Tomita (ORCID: https://orcid.org/0000-0003-1283-9009)
- Takeshi Kamiya (ORCID: https://orcid.org/0000-0001-8131-6696)
- Eikichi Ihara (ORCID: https://orcid.org/0000-0002-7070-6610)
- Tatsuya Abe (ORCID: https://orcid.org/0000-0002-7215-3597)
- Hiroshi Yajima (ORCID: https://orcid.org/0000-0003-3417-3148)
- Haruei Ogino (ORCID: https://orcid.org/0000-0003-0703-8389)
- Tomohiko Machida
- Toshihiro Noake
- Hiroshi Yamawaki
- Yasumi Araki
Institutions
- Kyushu University (JP)
- The Japanese Society of Gastroenterological Surgery (JP)
Publication Details
- Journal
- Digestion
- Published
- 2024-08-19
- DOI
- https://doi.org/10.1159/000540912
- Citations
- 22
- Primary Topic
- Gastrointestinal motility and disorders
- Type
- article
- Field-Weighted Citation Impact
- 10.21